Screen for weight and muscle loss before treatment planning by asking 3 simple questions3*
CONSIDER THE IMPACT OF LOW MUSCLE MASS TO YOUR TREATMENT PLAN
>30
studies showed higher rates of dose-limiting toxicity in patients with low muscle mass4
44%
higher risk of post-surgical complications with various solid tumors5
27%
higher overall mortality risk in colorectal cancer6
References:
1. Cespedes Feliciano EM, et al. Cancer. 2017;123(24):4868-4877. 2. Kurk, et al. J Cachexia Sarcopenia Muscle. 2019;10(4):803-813. 3. Muscaritoli M, et al. Cancers. 2023;15(2):380. 4. Daly LE, et al. Proc Nutr Soc. 2018;77(2):135-151 5. Weerink LBM, et al. J Cachexia Sarcopenia Muscle. 2020;11(3):636-649. 6. Caan BJ, et al. Cancer Epidemiol Biomarkers Prev. 2017;26(7):1008-1015.
Cancer- and treatment-related nutritional challenges contribute to muscle loss
Review how hypermetabolism + reduced consumption + systemic inflammation contribute to muscle loss7-14
Diet alone is often insufficient to meet the increased nutritional needs of patients with cancer.
ONS INITIATED BEFORE OR AT THE START OF ANTICANCER TREATMENT IS ASSOCIATED WITH FEWER TREATMENT DISRUPTIONS
Oral nutritional supplements (ONS) have been shown to help maintain body weight and muscle mass and support treatment tolerance15,16
High-protein ONS are proven to positively impact muscle mass in patients with cancer15,17,18
Our high-protein low-volume oral nutritional supplement range
85% COMPLIANCE OVER A 3-MONTH PERIOD19
Fortisip Compact Protein
Small-volume, nutrient-dense 125 ml format designed to:
- Support muscle mass
- Address insufficient nutritional intake
- Target inflammation
- Help address taste alterations
Fortisip Compact Protein is a food for special medical purposes for the dietary management of patients with or at risk of disease related malnutrition due to cancer, chronic catabolic disease or cachexia. Our Sensory Adapted Flavours range is made of specially designed flavours for patients with taste alterations. These products must be used under medical supervision.
Clinical studies with Fortisip Compact Protein have demonstrated:
- Improved muscle function1
References: 1. Grupinska, et al. Nutrients. 2021;13(10):3549.
- Recommended use: 2 servings per day
Adjustable to 1-2 servings based on individual nutritional needs. ONS should be consumed between meals to support nutritional intake without displacing food.1
- Recommended duration: At least 28 days
Nutritional and clinical benefits of ONS are typically observed when used for at least 28 days.2-6 Regular follow up is essential. Check adherence within the first week and monitor nutritional status every 2-4 weeks for the first 3 months.1
ESMO guidelines recommend early nutritional intervention, particularly for patients receiving anticancer treatments with high risk of inducing malnutrition.7 Omega-3 enriched ONS may be considered in patients receiving chemo-, radio-, or chemoradiotherapy.7
ONS=oral nutritional supplement.
References: 1. Bahat, et al. Clin Nutr. 2025;75:106552. 2. Holeckova, et al. Clin Nutr ESPEN. 2024;63:P1301. 3. Scannell, et al. Clin Nutr ESPEN. 2025;69:1177. 4. Grupinska, et al. Nutrients. 2021;13(10):3549. 5. Zietarska, et al. Nutrients 2017;9(10):1108. 6. Dingemans AM, et al. Nutrients. 2023; 15(24):5030. 7. Arends J, et al. ESMO Open. 2021;6(3):100092. Fortisip Compact Protein is a FOOD FOR SPECIAL MEDICAL PURPOSES for the dietary management of patients with or at risk of disease related malnutrition due to cancer, chronic catabolic disease or cachexia. Must be used under medical supervision.
Small-volume, nutrient-dense 125 ml format:
- Gluten free (<20 mg/kg)
- Halal
- Allergens: Milk, soy, fish
The widest variety of ONS flavours*
Peach mango | Berries | Mocha | Vanilla Strawberry | Banana | Neutral
Sensory-adapted formula for patients with taste alterations
Cool Red Fruits | Hot Tropical Ginger
ONS=oral nutritional supplement.
*Widest variety of flavours among high energy, high protein, 125ml ONS in the UK (April MIMS 2026).
HOW SENSORY-ADAPTED FORMULA CAN HELP ADDRESS TASTE ALTERATIONS
~7/10 patients with cancer report appetite loss and taste changes during treatment11,12
Up to 80% of patients think sensory adapted range helps with changes in taste and smell†‡
†Based on 2 tested variants.
Home Usage Test by Eolas International, (2023 and 2024) among patients diagnosed with cancer. Patients asked whether they agree (%) that the product helps them cope with changes in taste or smell.
Scores per product, number of patients (N) and country: Fortisip Compact Protein Cool Red Fruits: N = 135; 73% (IT) – 87% (NL).
Our Services
- Kurk, et al. J Cachexia Sarcopenia Muscle. 2019;10(4):803-813.
- Cespedes Feliciano EM, et al. Cancer. 2017;123(24):4868-4877.
- Muscaritoli M, et al. Cancers. 2023;15(2):380.
- Daly LE, et al. Proc Nutr Soc. 2018;77(2):135-151
- Weerink LBM, et al. J Cachexia Sarcopenia Muscle. 2020;11(3):636-649.
- Caan BJ, et al. Cancer Epidemiol Biomarkers Prev. 2017;26(7):1008-1015.
- Baracos V, et al. Nat Rev Dis Primers. 2018:4:17105.
- Stobaus N, et al. Nutr Cancer. 2015; 67(5):818-24.
- Hasegawa Y, et al. Clin Nutr. 2021; 40(7):4792-4798.
- Prado CMM, et al. Can J Diet Pract Res. 2012;73(4):e298-303.
- Spotten, et al. Ann Oncol. 2017; 28(5):969-984.
- Data on file: IPSOS, Nutrition in Cancer Care survey (2023).
- Arends J, et al. Clin Nutr. 2017;36(5), 1187-1196.
- Muscaritoli M, et al. Oncotarget. 2017;8(45):79884-79896.
- Meng Q, et al. Clin Nutr. 2021;40(1):40-46.
- Cereda E, et al. Radiother Oncol. 2018;126(1):81-88.
- Grupinska, et al. Nutrients. 2021;13(10):3549.
- Orsso, et al. Am J Clin Nutr. 2024;120(6):1311-1324.
- Holeckova, et al. Clin Nutr ESPEN. 2024;63:P1301.
- Dingemans AM, et al. Nutrients. 2023;15(24):5030.
Fortisip Compact Protein is a FOOD FOR SPECIAL MEDICAL PURPOSES for the dietary management of disease related malnutrition. Our Sensory Adapted Flavours range is made of specially designed flavours for patients with taste alterations. These products must be used under medical supervision.
